Pharma & Healthcare
Global Unfractionated Heparin Market Research Report 2025
- Jun 28, 25
- ID: 343795
- Pages: 106
- Figures: 104
- Views: 1
The global market for Unfractionated Heparin was valued at US$ 1049 million in the year 2024 and is projected to reach a revised size of US$ 1339 million by 2031, growing at a CAGR of 3.6% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Unfractionated Heparin competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Unfractionated Heparin (UFH) is a fast-acting anticoagulant (blood thinner) used to prevent and treat blood clots. It is derived from animal tissues (usually pig intestines or cow lungs) and consists of a mixture of glycosaminoglycan chains of varying lengths.
Although heparin can be synthesized by means of chemical processes, most of the worldwide produced heparin is extracted from animal tissue, porcine intestinal mucosa specifically. The production of heparin is located near the source of raw material. Area’s like China, North America and Europa are the main pork producing areas and these are also the locations of the main heparin producers. More than 65% of the world's heparin APIs are supplied by Chinese companies.
Heparin’s main source, porcine intestinal mucosa, is a by-product of pork slaughtering and is released while cleaning the pork’s casing. Cleaning casings is a specialized process that requires highly skilled staff and state of the art equipment. To avoid degradation of the heparin content and decay, stabilizing agent is added directly after harvesting. The material is stored in bulk tanks awaiting transport to the processing facility. There are also some Bovine-derived APIs on the market, but they are very few, accounting for about 2% to 4% of the global market share.
The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Unfractionated Heparin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Unfractionated Heparin.
The Unfractionated Heparin market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Unfractionated Heparin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Unfractionated Heparin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sanofi
Pfizer
Organon Canada
Leo Pharma
Panpharma
Rotexmedica GmbH
Bharat Serums and Vaccines
Troikaa Pharmaceuticals
Wellona Pharma
B. Braun
Bioiberica
Sagent Pharmaceuticals, Inc
Gland Pharma Limited
Stanex
Mylan
Rewine Pharmaceutical
Jianyou Pharmaceutical
Shenzhen Techdow Pharmaceutical
Changshan Pharma
Dongcheng Pharmaceutical
Segment by Type
Heparin Sodium
Heparin Calcium
Segment by Application
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Myocardial Infarction
Unstable Angina
Atrial Fibrillation-related Clots
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Unfractionated Heparin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Unfractionated Heparin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Unfractionated Heparin competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Unfractionated Heparin (UFH) is a fast-acting anticoagulant (blood thinner) used to prevent and treat blood clots. It is derived from animal tissues (usually pig intestines or cow lungs) and consists of a mixture of glycosaminoglycan chains of varying lengths.
Although heparin can be synthesized by means of chemical processes, most of the worldwide produced heparin is extracted from animal tissue, porcine intestinal mucosa specifically. The production of heparin is located near the source of raw material. Area’s like China, North America and Europa are the main pork producing areas and these are also the locations of the main heparin producers. More than 65% of the world's heparin APIs are supplied by Chinese companies.
Heparin’s main source, porcine intestinal mucosa, is a by-product of pork slaughtering and is released while cleaning the pork’s casing. Cleaning casings is a specialized process that requires highly skilled staff and state of the art equipment. To avoid degradation of the heparin content and decay, stabilizing agent is added directly after harvesting. The material is stored in bulk tanks awaiting transport to the processing facility. There are also some Bovine-derived APIs on the market, but they are very few, accounting for about 2% to 4% of the global market share.
The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Unfractionated Heparin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Unfractionated Heparin.
The Unfractionated Heparin market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Unfractionated Heparin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Unfractionated Heparin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sanofi
Pfizer
Organon Canada
Leo Pharma
Panpharma
Rotexmedica GmbH
Bharat Serums and Vaccines
Troikaa Pharmaceuticals
Wellona Pharma
B. Braun
Bioiberica
Sagent Pharmaceuticals, Inc
Gland Pharma Limited
Stanex
Mylan
Rewine Pharmaceutical
Jianyou Pharmaceutical
Shenzhen Techdow Pharmaceutical
Changshan Pharma
Dongcheng Pharmaceutical
Segment by Type
Heparin Sodium
Heparin Calcium
Segment by Application
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Myocardial Infarction
Unstable Angina
Atrial Fibrillation-related Clots
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Unfractionated Heparin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Unfractionated Heparin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Unfractionated Heparin Market Overview
1.1 Product Definition
1.2 Unfractionated Heparin by Type
1.2.1 Global Unfractionated Heparin Market Value Comparison by Type (2024 VS 2031)
1.2.2 Heparin Sodium
1.2.3 Heparin Calcium
1.3 Unfractionated Heparin by Application
1.3.1 Global Unfractionated Heparin Market Value by Application (2024 VS 2031)
1.3.2 Deep Vein Thrombosis (DVT)
1.3.3 Pulmonary Embolism (PE)
1.3.4 Myocardial Infarction
1.3.5 Unstable Angina
1.3.6 Atrial Fibrillation-related Clots
1.3.7 Other
1.4 Global Unfractionated Heparin Market Size Estimates and Forecasts
1.4.1 Global Unfractionated Heparin Revenue 2020-2031
1.4.2 Global Unfractionated Heparin Sales 2020-2031
1.4.3 Global Unfractionated Heparin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Unfractionated Heparin Market Competition by Manufacturers
2.1 Global Unfractionated Heparin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Unfractionated Heparin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Unfractionated Heparin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Unfractionated Heparin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Unfractionated Heparin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Unfractionated Heparin, Product Type & Application
2.7 Global Key Manufacturers of Unfractionated Heparin, Date of Enter into This Industry
2.8 Global Unfractionated Heparin Market Competitive Situation and Trends
2.8.1 Global Unfractionated Heparin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Unfractionated Heparin Players Market Share by Revenue
2.8.3 Global Unfractionated Heparin Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Unfractionated Heparin Market Scenario by Region
3.1 Global Unfractionated Heparin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Unfractionated Heparin Sales by Region: 2020-2031
3.2.1 Global Unfractionated Heparin Sales by Region: 2020-2025
3.2.2 Global Unfractionated Heparin Sales by Region: 2026-2031
3.3 Global Unfractionated Heparin Revenue by Region: 2020-2031
3.3.1 Global Unfractionated Heparin Revenue by Region: 2020-2025
3.3.2 Global Unfractionated Heparin Revenue by Region: 2026-2031
3.4 North America Unfractionated Heparin Market Facts & Figures by Country
3.4.1 North America Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Unfractionated Heparin Sales by Country (2020-2031)
3.4.3 North America Unfractionated Heparin Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Unfractionated Heparin Market Facts & Figures by Country
3.5.1 Europe Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Unfractionated Heparin Sales by Country (2020-2031)
3.5.3 Europe Unfractionated Heparin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Unfractionated Heparin Market Facts & Figures by Region
3.6.1 Asia Pacific Unfractionated Heparin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Unfractionated Heparin Sales by Region (2020-2031)
3.6.3 Asia Pacific Unfractionated Heparin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Unfractionated Heparin Market Facts & Figures by Country
3.7.1 Latin America Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Unfractionated Heparin Sales by Country (2020-2031)
3.7.3 Latin America Unfractionated Heparin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Unfractionated Heparin Market Facts & Figures by Country
3.8.1 Middle East and Africa Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Unfractionated Heparin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Unfractionated Heparin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Unfractionated Heparin Sales by Type (2020-2031)
4.1.1 Global Unfractionated Heparin Sales by Type (2020-2025)
4.1.2 Global Unfractionated Heparin Sales by Type (2026-2031)
4.1.3 Global Unfractionated Heparin Sales Market Share by Type (2020-2031)
4.2 Global Unfractionated Heparin Revenue by Type (2020-2031)
4.2.1 Global Unfractionated Heparin Revenue by Type (2020-2025)
4.2.2 Global Unfractionated Heparin Revenue by Type (2026-2031)
4.2.3 Global Unfractionated Heparin Revenue Market Share by Type (2020-2031)
4.3 Global Unfractionated Heparin Price by Type (2020-2031)
5 Segment by Application
5.1 Global Unfractionated Heparin Sales by Application (2020-2031)
5.1.1 Global Unfractionated Heparin Sales by Application (2020-2025)
5.1.2 Global Unfractionated Heparin Sales by Application (2026-2031)
5.1.3 Global Unfractionated Heparin Sales Market Share by Application (2020-2031)
5.2 Global Unfractionated Heparin Revenue by Application (2020-2031)
5.2.1 Global Unfractionated Heparin Revenue by Application (2020-2025)
5.2.2 Global Unfractionated Heparin Revenue by Application (2026-2031)
5.2.3 Global Unfractionated Heparin Revenue Market Share by Application (2020-2031)
5.3 Global Unfractionated Heparin Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Unfractionated Heparin Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Unfractionated Heparin Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon Canada
6.3.1 Organon Canada Company Information
6.3.2 Organon Canada Description and Business Overview
6.3.3 Organon Canada Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Organon Canada Unfractionated Heparin Product Portfolio
6.3.5 Organon Canada Recent Developments/Updates
6.4 Leo Pharma
6.4.1 Leo Pharma Company Information
6.4.2 Leo Pharma Description and Business Overview
6.4.3 Leo Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Leo Pharma Unfractionated Heparin Product Portfolio
6.4.5 Leo Pharma Recent Developments/Updates
6.5 Panpharma
6.5.1 Panpharma Company Information
6.5.2 Panpharma Description and Business Overview
6.5.3 Panpharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Panpharma Unfractionated Heparin Product Portfolio
6.5.5 Panpharma Recent Developments/Updates
6.6 Rotexmedica GmbH
6.6.1 Rotexmedica GmbH Company Information
6.6.2 Rotexmedica GmbH Description and Business Overview
6.6.3 Rotexmedica GmbH Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Rotexmedica GmbH Unfractionated Heparin Product Portfolio
6.6.5 Rotexmedica GmbH Recent Developments/Updates
6.7 Bharat Serums and Vaccines
6.7.1 Bharat Serums and Vaccines Company Information
6.7.2 Bharat Serums and Vaccines Description and Business Overview
6.7.3 Bharat Serums and Vaccines Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bharat Serums and Vaccines Unfractionated Heparin Product Portfolio
6.7.5 Bharat Serums and Vaccines Recent Developments/Updates
6.8 Troikaa Pharmaceuticals
6.8.1 Troikaa Pharmaceuticals Company Information
6.8.2 Troikaa Pharmaceuticals Description and Business Overview
6.8.3 Troikaa Pharmaceuticals Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolio
6.8.5 Troikaa Pharmaceuticals Recent Developments/Updates
6.9 Wellona Pharma
6.9.1 Wellona Pharma Company Information
6.9.2 Wellona Pharma Description and Business Overview
6.9.3 Wellona Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Wellona Pharma Unfractionated Heparin Product Portfolio
6.9.5 Wellona Pharma Recent Developments/Updates
6.10 B. Braun
6.10.1 B. Braun Company Information
6.10.2 B. Braun Description and Business Overview
6.10.3 B. Braun Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.10.4 B. Braun Unfractionated Heparin Product Portfolio
6.10.5 B. Braun Recent Developments/Updates
6.11 Bioiberica
6.11.1 Bioiberica Company Information
6.11.2 Bioiberica Description and Business Overview
6.11.3 Bioiberica Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bioiberica Unfractionated Heparin Product Portfolio
6.11.5 Bioiberica Recent Developments/Updates
6.12 Sagent Pharmaceuticals, Inc
6.12.1 Sagent Pharmaceuticals, Inc Company Information
6.12.2 Sagent Pharmaceuticals, Inc Description and Business Overview
6.12.3 Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolio
6.12.5 Sagent Pharmaceuticals, Inc Recent Developments/Updates
6.13 Gland Pharma Limited
6.13.1 Gland Pharma Limited Company Information
6.13.2 Gland Pharma Limited Description and Business Overview
6.13.3 Gland Pharma Limited Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Gland Pharma Limited Unfractionated Heparin Product Portfolio
6.13.5 Gland Pharma Limited Recent Developments/Updates
6.14 Stanex
6.14.1 Stanex Company Information
6.14.2 Stanex Description and Business Overview
6.14.3 Stanex Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Stanex Unfractionated Heparin Product Portfolio
6.14.5 Stanex Recent Developments/Updates
6.15 Mylan
6.15.1 Mylan Company Information
6.15.2 Mylan Description and Business Overview
6.15.3 Mylan Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Mylan Unfractionated Heparin Product Portfolio
6.15.5 Mylan Recent Developments/Updates
6.16 Rewine Pharmaceutical
6.16.1 Rewine Pharmaceutical Company Information
6.16.2 Rewine Pharmaceutical Description and Business Overview
6.16.3 Rewine Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Rewine Pharmaceutical Unfractionated Heparin Product Portfolio
6.16.5 Rewine Pharmaceutical Recent Developments/Updates
6.17 Jianyou Pharmaceutical
6.17.1 Jianyou Pharmaceutical Company Information
6.17.2 Jianyou Pharmaceutical Description and Business Overview
6.17.3 Jianyou Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Jianyou Pharmaceutical Unfractionated Heparin Product Portfolio
6.17.5 Jianyou Pharmaceutical Recent Developments/Updates
6.18 Shenzhen Techdow Pharmaceutical
6.18.1 Shenzhen Techdow Pharmaceutical Company Information
6.18.2 Shenzhen Techdow Pharmaceutical Description and Business Overview
6.18.3 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolio
6.18.5 Shenzhen Techdow Pharmaceutical Recent Developments/Updates
6.19 Changshan Pharma
6.19.1 Changshan Pharma Company Information
6.19.2 Changshan Pharma Description and Business Overview
6.19.3 Changshan Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Changshan Pharma Unfractionated Heparin Product Portfolio
6.19.5 Changshan Pharma Recent Developments/Updates
6.20 Dongcheng Pharmaceutical
6.20.1 Dongcheng Pharmaceutical Company Information
6.20.2 Dongcheng Pharmaceutical Description and Business Overview
6.20.3 Dongcheng Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolio
6.20.5 Dongcheng Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Unfractionated Heparin Industry Chain Analysis
7.2 Unfractionated Heparin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Unfractionated Heparin Production Mode & Process Analysis
7.4 Unfractionated Heparin Sales and Marketing
7.4.1 Unfractionated Heparin Sales Channels
7.4.2 Unfractionated Heparin Distributors
7.5 Unfractionated Heparin Customer Analysis
8 Unfractionated Heparin Market Dynamics
8.1 Unfractionated Heparin Industry Trends
8.2 Unfractionated Heparin Market Drivers
8.3 Unfractionated Heparin Market Challenges
8.4 Unfractionated Heparin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Unfractionated Heparin by Type
1.2.1 Global Unfractionated Heparin Market Value Comparison by Type (2024 VS 2031)
1.2.2 Heparin Sodium
1.2.3 Heparin Calcium
1.3 Unfractionated Heparin by Application
1.3.1 Global Unfractionated Heparin Market Value by Application (2024 VS 2031)
1.3.2 Deep Vein Thrombosis (DVT)
1.3.3 Pulmonary Embolism (PE)
1.3.4 Myocardial Infarction
1.3.5 Unstable Angina
1.3.6 Atrial Fibrillation-related Clots
1.3.7 Other
1.4 Global Unfractionated Heparin Market Size Estimates and Forecasts
1.4.1 Global Unfractionated Heparin Revenue 2020-2031
1.4.2 Global Unfractionated Heparin Sales 2020-2031
1.4.3 Global Unfractionated Heparin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Unfractionated Heparin Market Competition by Manufacturers
2.1 Global Unfractionated Heparin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Unfractionated Heparin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Unfractionated Heparin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Unfractionated Heparin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Unfractionated Heparin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Unfractionated Heparin, Product Type & Application
2.7 Global Key Manufacturers of Unfractionated Heparin, Date of Enter into This Industry
2.8 Global Unfractionated Heparin Market Competitive Situation and Trends
2.8.1 Global Unfractionated Heparin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Unfractionated Heparin Players Market Share by Revenue
2.8.3 Global Unfractionated Heparin Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Unfractionated Heparin Market Scenario by Region
3.1 Global Unfractionated Heparin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Unfractionated Heparin Sales by Region: 2020-2031
3.2.1 Global Unfractionated Heparin Sales by Region: 2020-2025
3.2.2 Global Unfractionated Heparin Sales by Region: 2026-2031
3.3 Global Unfractionated Heparin Revenue by Region: 2020-2031
3.3.1 Global Unfractionated Heparin Revenue by Region: 2020-2025
3.3.2 Global Unfractionated Heparin Revenue by Region: 2026-2031
3.4 North America Unfractionated Heparin Market Facts & Figures by Country
3.4.1 North America Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Unfractionated Heparin Sales by Country (2020-2031)
3.4.3 North America Unfractionated Heparin Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Unfractionated Heparin Market Facts & Figures by Country
3.5.1 Europe Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Unfractionated Heparin Sales by Country (2020-2031)
3.5.3 Europe Unfractionated Heparin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Unfractionated Heparin Market Facts & Figures by Region
3.6.1 Asia Pacific Unfractionated Heparin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Unfractionated Heparin Sales by Region (2020-2031)
3.6.3 Asia Pacific Unfractionated Heparin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Unfractionated Heparin Market Facts & Figures by Country
3.7.1 Latin America Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Unfractionated Heparin Sales by Country (2020-2031)
3.7.3 Latin America Unfractionated Heparin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Unfractionated Heparin Market Facts & Figures by Country
3.8.1 Middle East and Africa Unfractionated Heparin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Unfractionated Heparin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Unfractionated Heparin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Unfractionated Heparin Sales by Type (2020-2031)
4.1.1 Global Unfractionated Heparin Sales by Type (2020-2025)
4.1.2 Global Unfractionated Heparin Sales by Type (2026-2031)
4.1.3 Global Unfractionated Heparin Sales Market Share by Type (2020-2031)
4.2 Global Unfractionated Heparin Revenue by Type (2020-2031)
4.2.1 Global Unfractionated Heparin Revenue by Type (2020-2025)
4.2.2 Global Unfractionated Heparin Revenue by Type (2026-2031)
4.2.3 Global Unfractionated Heparin Revenue Market Share by Type (2020-2031)
4.3 Global Unfractionated Heparin Price by Type (2020-2031)
5 Segment by Application
5.1 Global Unfractionated Heparin Sales by Application (2020-2031)
5.1.1 Global Unfractionated Heparin Sales by Application (2020-2025)
5.1.2 Global Unfractionated Heparin Sales by Application (2026-2031)
5.1.3 Global Unfractionated Heparin Sales Market Share by Application (2020-2031)
5.2 Global Unfractionated Heparin Revenue by Application (2020-2031)
5.2.1 Global Unfractionated Heparin Revenue by Application (2020-2025)
5.2.2 Global Unfractionated Heparin Revenue by Application (2026-2031)
5.2.3 Global Unfractionated Heparin Revenue Market Share by Application (2020-2031)
5.3 Global Unfractionated Heparin Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Unfractionated Heparin Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Unfractionated Heparin Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon Canada
6.3.1 Organon Canada Company Information
6.3.2 Organon Canada Description and Business Overview
6.3.3 Organon Canada Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Organon Canada Unfractionated Heparin Product Portfolio
6.3.5 Organon Canada Recent Developments/Updates
6.4 Leo Pharma
6.4.1 Leo Pharma Company Information
6.4.2 Leo Pharma Description and Business Overview
6.4.3 Leo Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Leo Pharma Unfractionated Heparin Product Portfolio
6.4.5 Leo Pharma Recent Developments/Updates
6.5 Panpharma
6.5.1 Panpharma Company Information
6.5.2 Panpharma Description and Business Overview
6.5.3 Panpharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Panpharma Unfractionated Heparin Product Portfolio
6.5.5 Panpharma Recent Developments/Updates
6.6 Rotexmedica GmbH
6.6.1 Rotexmedica GmbH Company Information
6.6.2 Rotexmedica GmbH Description and Business Overview
6.6.3 Rotexmedica GmbH Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Rotexmedica GmbH Unfractionated Heparin Product Portfolio
6.6.5 Rotexmedica GmbH Recent Developments/Updates
6.7 Bharat Serums and Vaccines
6.7.1 Bharat Serums and Vaccines Company Information
6.7.2 Bharat Serums and Vaccines Description and Business Overview
6.7.3 Bharat Serums and Vaccines Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bharat Serums and Vaccines Unfractionated Heparin Product Portfolio
6.7.5 Bharat Serums and Vaccines Recent Developments/Updates
6.8 Troikaa Pharmaceuticals
6.8.1 Troikaa Pharmaceuticals Company Information
6.8.2 Troikaa Pharmaceuticals Description and Business Overview
6.8.3 Troikaa Pharmaceuticals Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolio
6.8.5 Troikaa Pharmaceuticals Recent Developments/Updates
6.9 Wellona Pharma
6.9.1 Wellona Pharma Company Information
6.9.2 Wellona Pharma Description and Business Overview
6.9.3 Wellona Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Wellona Pharma Unfractionated Heparin Product Portfolio
6.9.5 Wellona Pharma Recent Developments/Updates
6.10 B. Braun
6.10.1 B. Braun Company Information
6.10.2 B. Braun Description and Business Overview
6.10.3 B. Braun Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.10.4 B. Braun Unfractionated Heparin Product Portfolio
6.10.5 B. Braun Recent Developments/Updates
6.11 Bioiberica
6.11.1 Bioiberica Company Information
6.11.2 Bioiberica Description and Business Overview
6.11.3 Bioiberica Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bioiberica Unfractionated Heparin Product Portfolio
6.11.5 Bioiberica Recent Developments/Updates
6.12 Sagent Pharmaceuticals, Inc
6.12.1 Sagent Pharmaceuticals, Inc Company Information
6.12.2 Sagent Pharmaceuticals, Inc Description and Business Overview
6.12.3 Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolio
6.12.5 Sagent Pharmaceuticals, Inc Recent Developments/Updates
6.13 Gland Pharma Limited
6.13.1 Gland Pharma Limited Company Information
6.13.2 Gland Pharma Limited Description and Business Overview
6.13.3 Gland Pharma Limited Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Gland Pharma Limited Unfractionated Heparin Product Portfolio
6.13.5 Gland Pharma Limited Recent Developments/Updates
6.14 Stanex
6.14.1 Stanex Company Information
6.14.2 Stanex Description and Business Overview
6.14.3 Stanex Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Stanex Unfractionated Heparin Product Portfolio
6.14.5 Stanex Recent Developments/Updates
6.15 Mylan
6.15.1 Mylan Company Information
6.15.2 Mylan Description and Business Overview
6.15.3 Mylan Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Mylan Unfractionated Heparin Product Portfolio
6.15.5 Mylan Recent Developments/Updates
6.16 Rewine Pharmaceutical
6.16.1 Rewine Pharmaceutical Company Information
6.16.2 Rewine Pharmaceutical Description and Business Overview
6.16.3 Rewine Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Rewine Pharmaceutical Unfractionated Heparin Product Portfolio
6.16.5 Rewine Pharmaceutical Recent Developments/Updates
6.17 Jianyou Pharmaceutical
6.17.1 Jianyou Pharmaceutical Company Information
6.17.2 Jianyou Pharmaceutical Description and Business Overview
6.17.3 Jianyou Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Jianyou Pharmaceutical Unfractionated Heparin Product Portfolio
6.17.5 Jianyou Pharmaceutical Recent Developments/Updates
6.18 Shenzhen Techdow Pharmaceutical
6.18.1 Shenzhen Techdow Pharmaceutical Company Information
6.18.2 Shenzhen Techdow Pharmaceutical Description and Business Overview
6.18.3 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolio
6.18.5 Shenzhen Techdow Pharmaceutical Recent Developments/Updates
6.19 Changshan Pharma
6.19.1 Changshan Pharma Company Information
6.19.2 Changshan Pharma Description and Business Overview
6.19.3 Changshan Pharma Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Changshan Pharma Unfractionated Heparin Product Portfolio
6.19.5 Changshan Pharma Recent Developments/Updates
6.20 Dongcheng Pharmaceutical
6.20.1 Dongcheng Pharmaceutical Company Information
6.20.2 Dongcheng Pharmaceutical Description and Business Overview
6.20.3 Dongcheng Pharmaceutical Unfractionated Heparin Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolio
6.20.5 Dongcheng Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Unfractionated Heparin Industry Chain Analysis
7.2 Unfractionated Heparin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Unfractionated Heparin Production Mode & Process Analysis
7.4 Unfractionated Heparin Sales and Marketing
7.4.1 Unfractionated Heparin Sales Channels
7.4.2 Unfractionated Heparin Distributors
7.5 Unfractionated Heparin Customer Analysis
8 Unfractionated Heparin Market Dynamics
8.1 Unfractionated Heparin Industry Trends
8.2 Unfractionated Heparin Market Drivers
8.3 Unfractionated Heparin Market Challenges
8.4 Unfractionated Heparin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Unfractionated Heparin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Unfractionated Heparin Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Unfractionated Heparin Market Competitive Situation by Manufacturers in 2024
Table 4. Global Unfractionated Heparin Sales (K Dose) of Key Manufacturers (2020-2025)
Table 5. Global Unfractionated Heparin Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Unfractionated Heparin Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Unfractionated Heparin Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Unfractionated Heparin Average Price (US$/Dose) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Unfractionated Heparin, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Unfractionated Heparin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Unfractionated Heparin, Product Type & Application
Table 12. Global Key Manufacturers of Unfractionated Heparin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Unfractionated Heparin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Unfractionated Heparin as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Unfractionated Heparin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Unfractionated Heparin Sales by Region (2020-2025) & (K Dose)
Table 18. Global Unfractionated Heparin Sales Market Share by Region (2020-2025)
Table 19. Global Unfractionated Heparin Sales by Region (2026-2031) & (K Dose)
Table 20. Global Unfractionated Heparin Sales Market Share by Region (2026-2031)
Table 21. Global Unfractionated Heparin Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Unfractionated Heparin Revenue Market Share by Region (2020-2025)
Table 23. Global Unfractionated Heparin Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Unfractionated Heparin Revenue Market Share by Region (2026-2031)
Table 25. North America Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 27. North America Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 28. North America Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 32. Europe Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 33. Europe Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Unfractionated Heparin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Unfractionated Heparin Sales by Region (2020-2025) & (K Dose)
Table 37. Asia Pacific Unfractionated Heparin Sales by Region (2026-2031) & (K Dose)
Table 38. Asia Pacific Unfractionated Heparin Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Unfractionated Heparin Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 42. Latin America Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 43. Latin America Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 47. Middle East and Africa Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 48. Middle East and Africa Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Unfractionated Heparin Sales (K Dose) by Type (2020-2025)
Table 51. Global Unfractionated Heparin Sales (K Dose) by Type (2026-2031)
Table 52. Global Unfractionated Heparin Sales Market Share by Type (2020-2025)
Table 53. Global Unfractionated Heparin Sales Market Share by Type (2026-2031)
Table 54. Global Unfractionated Heparin Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Unfractionated Heparin Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Unfractionated Heparin Revenue Market Share by Type (2020-2025)
Table 57. Global Unfractionated Heparin Revenue Market Share by Type (2026-2031)
Table 58. Global Unfractionated Heparin Price (US$/Dose) by Type (2020-2025)
Table 59. Global Unfractionated Heparin Price (US$/Dose) by Type (2026-2031)
Table 60. Global Unfractionated Heparin Sales (K Dose) by Application (2020-2025)
Table 61. Global Unfractionated Heparin Sales (K Dose) by Application (2026-2031)
Table 62. Global Unfractionated Heparin Sales Market Share by Application (2020-2025)
Table 63. Global Unfractionated Heparin Sales Market Share by Application (2026-2031)
Table 64. Global Unfractionated Heparin Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Unfractionated Heparin Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Unfractionated Heparin Revenue Market Share by Application (2020-2025)
Table 67. Global Unfractionated Heparin Revenue Market Share by Application (2026-2031)
Table 68. Global Unfractionated Heparin Price (US$/Dose) by Application (2020-2025)
Table 69. Global Unfractionated Heparin Price (US$/Dose) by Application (2026-2031)
Table 70. Sanofi Company Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. Sanofi Unfractionated Heparin Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Pfizer Company Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. Pfizer Unfractionated Heparin Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Organon Canada Company Information
Table 81. Organon Canada Description and Business Overview
Table 82. Organon Canada Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. Organon Canada Unfractionated Heparin Product
Table 84. Organon Canada Recent Developments/Updates
Table 85. Leo Pharma Company Information
Table 86. Leo Pharma Description and Business Overview
Table 87. Leo Pharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. Leo Pharma Unfractionated Heparin Product
Table 89. Leo Pharma Recent Developments/Updates
Table 90. Panpharma Company Information
Table 91. Panpharma Description and Business Overview
Table 92. Panpharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Panpharma Unfractionated Heparin Product
Table 94. Panpharma Recent Developments/Updates
Table 95. Rotexmedica GmbH Company Information
Table 96. Rotexmedica GmbH Description and Business Overview
Table 97. Rotexmedica GmbH Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. Rotexmedica GmbH Unfractionated Heparin Product
Table 99. Rotexmedica GmbH Recent Developments/Updates
Table 100. Bharat Serums and Vaccines Company Information
Table 101. Bharat Serums and Vaccines Description and Business Overview
Table 102. Bharat Serums and Vaccines Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 103. Bharat Serums and Vaccines Unfractionated Heparin Product
Table 104. Bharat Serums and Vaccines Recent Developments/Updates
Table 105. Troikaa Pharmaceuticals Company Information
Table 106. Troikaa Pharmaceuticals Description and Business Overview
Table 107. Troikaa Pharmaceuticals Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 108. Troikaa Pharmaceuticals Unfractionated Heparin Product
Table 109. Troikaa Pharmaceuticals Recent Developments/Updates
Table 110. Wellona Pharma Company Information
Table 111. Wellona Pharma Description and Business Overview
Table 112. Wellona Pharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 113. Wellona Pharma Unfractionated Heparin Product
Table 114. Wellona Pharma Recent Developments/Updates
Table 115. B. Braun Company Information
Table 116. B. Braun Description and Business Overview
Table 117. B. Braun Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 118. B. Braun Unfractionated Heparin Product
Table 119. B. Braun Recent Developments/Updates
Table 120. Bioiberica Company Information
Table 121. Bioiberica Description and Business Overview
Table 122. Bioiberica Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 123. Bioiberica Unfractionated Heparin Product
Table 124. Bioiberica Recent Developments/Updates
Table 125. Sagent Pharmaceuticals, Inc Company Information
Table 126. Sagent Pharmaceuticals, Inc Description and Business Overview
Table 127. Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 128. Sagent Pharmaceuticals, Inc Unfractionated Heparin Product
Table 129. Sagent Pharmaceuticals, Inc Recent Developments/Updates
Table 130. Gland Pharma Limited Company Information
Table 131. Gland Pharma Limited Description and Business Overview
Table 132. Gland Pharma Limited Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 133. Gland Pharma Limited Unfractionated Heparin Product
Table 134. Gland Pharma Limited Recent Developments/Updates
Table 135. Stanex Company Information
Table 136. Stanex Description and Business Overview
Table 137. Stanex Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 138. Stanex Unfractionated Heparin Product
Table 139. Stanex Recent Developments/Updates
Table 140. Mylan Company Information
Table 141. Mylan Description and Business Overview
Table 142. Mylan Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 143. Mylan Unfractionated Heparin Product
Table 144. Mylan Recent Developments/Updates
Table 145. Rewine Pharmaceutical Company Information
Table 146. Rewine Pharmaceutical Description and Business Overview
Table 147. Rewine Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 148. Rewine Pharmaceutical Unfractionated Heparin Product
Table 149. Rewine Pharmaceutical Recent Developments/Updates
Table 150. Jianyou Pharmaceutical Company Information
Table 151. Jianyou Pharmaceutical Description and Business Overview
Table 152. Jianyou Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 153. Jianyou Pharmaceutical Unfractionated Heparin Product
Table 154. Jianyou Pharmaceutical Recent Developments/Updates
Table 155. Shenzhen Techdow Pharmaceutical Company Information
Table 156. Shenzhen Techdow Pharmaceutical Description and Business Overview
Table 157. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 158. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product
Table 159. Shenzhen Techdow Pharmaceutical Recent Developments/Updates
Table 160. Changshan Pharma Company Information
Table 161. Changshan Pharma Description and Business Overview
Table 162. Changshan Pharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 163. Changshan Pharma Unfractionated Heparin Product
Table 164. Changshan Pharma Recent Developments/Updates
Table 165. Dongcheng Pharmaceutical Company Information
Table 166. Dongcheng Pharmaceutical Description and Business Overview
Table 167. Dongcheng Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 168. Dongcheng Pharmaceutical Unfractionated Heparin Product
Table 169. Dongcheng Pharmaceutical Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Unfractionated Heparin Distributors List
Table 173. Unfractionated Heparin Customers List
Table 174. Unfractionated Heparin Market Trends
Table 175. Unfractionated Heparin Market Drivers
Table 176. Unfractionated Heparin Market Challenges
Table 177. Unfractionated Heparin Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
Table 181. Authors List of This Report
List of Figures
Figure 1. Product Picture of Unfractionated Heparin
Figure 2. Global Unfractionated Heparin Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Unfractionated Heparin Market Share by Type: 2024 & 2031
Figure 4. Heparin Sodium Product Picture
Figure 5. Heparin Calcium Product Picture
Figure 6. Global Unfractionated Heparin Market Value by Application (2020-2031) & (US$ Million)
Figure 7. Global Unfractionated Heparin Market Share by Application: 2024 & 2031
Figure 8. Deep Vein Thrombosis (DVT)
Figure 9. Pulmonary Embolism (PE)
Figure 10. Myocardial Infarction
Figure 11. Unstable Angina
Figure 12. Atrial Fibrillation-related Clots
Figure 13. Other
Figure 14. Global Unfractionated Heparin Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Unfractionated Heparin Market Size (2020-2031) & (US$ Million)
Figure 16. Global Unfractionated Heparin Sales (2020-2031) & (K Dose)
Figure 17. Global Unfractionated Heparin Average Price (US$/Dose) & (2020-2031)
Figure 18. Unfractionated Heparin Report Years Considered
Figure 19. Unfractionated Heparin Sales Share by Manufacturers in 2024
Figure 20. Global Unfractionated Heparin Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Unfractionated Heparin Players: Market Share by Revenue in Unfractionated Heparin in 2024
Figure 22. Unfractionated Heparin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Unfractionated Heparin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 25. North America Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 26. U.S. Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 29. Europe Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 30. Germany Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Unfractionated Heparin Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Unfractionated Heparin Revenue Market Share by Region (2020-2031)
Figure 37. China Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Taiwan Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Indonesia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Thailand Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Malaysia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Philippines Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Latin America Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 48. Latin America Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 49. Mexico Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Brazil Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Argentina Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Unfractionated Heparin by Type (2020-2031)
Figure 58. Global Revenue Market Share of Unfractionated Heparin by Type (2020-2031)
Figure 59. Global Unfractionated Heparin Price (US$/Dose) by Type (2020-2031)
Figure 60. Global Sales Market Share of Unfractionated Heparin by Application (2020-2031)
Figure 61. Global Revenue Market Share of Unfractionated Heparin by Application (2020-2031)
Figure 62. Global Unfractionated Heparin Price (US$/Dose) by Application (2020-2031)
Figure 63. Unfractionated Heparin Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Unfractionated Heparin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Unfractionated Heparin Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Unfractionated Heparin Market Competitive Situation by Manufacturers in 2024
Table 4. Global Unfractionated Heparin Sales (K Dose) of Key Manufacturers (2020-2025)
Table 5. Global Unfractionated Heparin Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Unfractionated Heparin Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Unfractionated Heparin Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Unfractionated Heparin Average Price (US$/Dose) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Unfractionated Heparin, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Unfractionated Heparin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Unfractionated Heparin, Product Type & Application
Table 12. Global Key Manufacturers of Unfractionated Heparin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Unfractionated Heparin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Unfractionated Heparin as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Unfractionated Heparin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Unfractionated Heparin Sales by Region (2020-2025) & (K Dose)
Table 18. Global Unfractionated Heparin Sales Market Share by Region (2020-2025)
Table 19. Global Unfractionated Heparin Sales by Region (2026-2031) & (K Dose)
Table 20. Global Unfractionated Heparin Sales Market Share by Region (2026-2031)
Table 21. Global Unfractionated Heparin Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Unfractionated Heparin Revenue Market Share by Region (2020-2025)
Table 23. Global Unfractionated Heparin Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Unfractionated Heparin Revenue Market Share by Region (2026-2031)
Table 25. North America Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 27. North America Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 28. North America Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 32. Europe Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 33. Europe Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Unfractionated Heparin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Unfractionated Heparin Sales by Region (2020-2025) & (K Dose)
Table 37. Asia Pacific Unfractionated Heparin Sales by Region (2026-2031) & (K Dose)
Table 38. Asia Pacific Unfractionated Heparin Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Unfractionated Heparin Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 42. Latin America Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 43. Latin America Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Unfractionated Heparin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Unfractionated Heparin Sales by Country (2020-2025) & (K Dose)
Table 47. Middle East and Africa Unfractionated Heparin Sales by Country (2026-2031) & (K Dose)
Table 48. Middle East and Africa Unfractionated Heparin Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Unfractionated Heparin Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Unfractionated Heparin Sales (K Dose) by Type (2020-2025)
Table 51. Global Unfractionated Heparin Sales (K Dose) by Type (2026-2031)
Table 52. Global Unfractionated Heparin Sales Market Share by Type (2020-2025)
Table 53. Global Unfractionated Heparin Sales Market Share by Type (2026-2031)
Table 54. Global Unfractionated Heparin Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Unfractionated Heparin Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Unfractionated Heparin Revenue Market Share by Type (2020-2025)
Table 57. Global Unfractionated Heparin Revenue Market Share by Type (2026-2031)
Table 58. Global Unfractionated Heparin Price (US$/Dose) by Type (2020-2025)
Table 59. Global Unfractionated Heparin Price (US$/Dose) by Type (2026-2031)
Table 60. Global Unfractionated Heparin Sales (K Dose) by Application (2020-2025)
Table 61. Global Unfractionated Heparin Sales (K Dose) by Application (2026-2031)
Table 62. Global Unfractionated Heparin Sales Market Share by Application (2020-2025)
Table 63. Global Unfractionated Heparin Sales Market Share by Application (2026-2031)
Table 64. Global Unfractionated Heparin Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Unfractionated Heparin Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Unfractionated Heparin Revenue Market Share by Application (2020-2025)
Table 67. Global Unfractionated Heparin Revenue Market Share by Application (2026-2031)
Table 68. Global Unfractionated Heparin Price (US$/Dose) by Application (2020-2025)
Table 69. Global Unfractionated Heparin Price (US$/Dose) by Application (2026-2031)
Table 70. Sanofi Company Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. Sanofi Unfractionated Heparin Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Pfizer Company Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. Pfizer Unfractionated Heparin Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Organon Canada Company Information
Table 81. Organon Canada Description and Business Overview
Table 82. Organon Canada Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. Organon Canada Unfractionated Heparin Product
Table 84. Organon Canada Recent Developments/Updates
Table 85. Leo Pharma Company Information
Table 86. Leo Pharma Description and Business Overview
Table 87. Leo Pharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. Leo Pharma Unfractionated Heparin Product
Table 89. Leo Pharma Recent Developments/Updates
Table 90. Panpharma Company Information
Table 91. Panpharma Description and Business Overview
Table 92. Panpharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Panpharma Unfractionated Heparin Product
Table 94. Panpharma Recent Developments/Updates
Table 95. Rotexmedica GmbH Company Information
Table 96. Rotexmedica GmbH Description and Business Overview
Table 97. Rotexmedica GmbH Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. Rotexmedica GmbH Unfractionated Heparin Product
Table 99. Rotexmedica GmbH Recent Developments/Updates
Table 100. Bharat Serums and Vaccines Company Information
Table 101. Bharat Serums and Vaccines Description and Business Overview
Table 102. Bharat Serums and Vaccines Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 103. Bharat Serums and Vaccines Unfractionated Heparin Product
Table 104. Bharat Serums and Vaccines Recent Developments/Updates
Table 105. Troikaa Pharmaceuticals Company Information
Table 106. Troikaa Pharmaceuticals Description and Business Overview
Table 107. Troikaa Pharmaceuticals Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 108. Troikaa Pharmaceuticals Unfractionated Heparin Product
Table 109. Troikaa Pharmaceuticals Recent Developments/Updates
Table 110. Wellona Pharma Company Information
Table 111. Wellona Pharma Description and Business Overview
Table 112. Wellona Pharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 113. Wellona Pharma Unfractionated Heparin Product
Table 114. Wellona Pharma Recent Developments/Updates
Table 115. B. Braun Company Information
Table 116. B. Braun Description and Business Overview
Table 117. B. Braun Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 118. B. Braun Unfractionated Heparin Product
Table 119. B. Braun Recent Developments/Updates
Table 120. Bioiberica Company Information
Table 121. Bioiberica Description and Business Overview
Table 122. Bioiberica Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 123. Bioiberica Unfractionated Heparin Product
Table 124. Bioiberica Recent Developments/Updates
Table 125. Sagent Pharmaceuticals, Inc Company Information
Table 126. Sagent Pharmaceuticals, Inc Description and Business Overview
Table 127. Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 128. Sagent Pharmaceuticals, Inc Unfractionated Heparin Product
Table 129. Sagent Pharmaceuticals, Inc Recent Developments/Updates
Table 130. Gland Pharma Limited Company Information
Table 131. Gland Pharma Limited Description and Business Overview
Table 132. Gland Pharma Limited Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 133. Gland Pharma Limited Unfractionated Heparin Product
Table 134. Gland Pharma Limited Recent Developments/Updates
Table 135. Stanex Company Information
Table 136. Stanex Description and Business Overview
Table 137. Stanex Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 138. Stanex Unfractionated Heparin Product
Table 139. Stanex Recent Developments/Updates
Table 140. Mylan Company Information
Table 141. Mylan Description and Business Overview
Table 142. Mylan Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 143. Mylan Unfractionated Heparin Product
Table 144. Mylan Recent Developments/Updates
Table 145. Rewine Pharmaceutical Company Information
Table 146. Rewine Pharmaceutical Description and Business Overview
Table 147. Rewine Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 148. Rewine Pharmaceutical Unfractionated Heparin Product
Table 149. Rewine Pharmaceutical Recent Developments/Updates
Table 150. Jianyou Pharmaceutical Company Information
Table 151. Jianyou Pharmaceutical Description and Business Overview
Table 152. Jianyou Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 153. Jianyou Pharmaceutical Unfractionated Heparin Product
Table 154. Jianyou Pharmaceutical Recent Developments/Updates
Table 155. Shenzhen Techdow Pharmaceutical Company Information
Table 156. Shenzhen Techdow Pharmaceutical Description and Business Overview
Table 157. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 158. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product
Table 159. Shenzhen Techdow Pharmaceutical Recent Developments/Updates
Table 160. Changshan Pharma Company Information
Table 161. Changshan Pharma Description and Business Overview
Table 162. Changshan Pharma Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 163. Changshan Pharma Unfractionated Heparin Product
Table 164. Changshan Pharma Recent Developments/Updates
Table 165. Dongcheng Pharmaceutical Company Information
Table 166. Dongcheng Pharmaceutical Description and Business Overview
Table 167. Dongcheng Pharmaceutical Unfractionated Heparin Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 168. Dongcheng Pharmaceutical Unfractionated Heparin Product
Table 169. Dongcheng Pharmaceutical Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Unfractionated Heparin Distributors List
Table 173. Unfractionated Heparin Customers List
Table 174. Unfractionated Heparin Market Trends
Table 175. Unfractionated Heparin Market Drivers
Table 176. Unfractionated Heparin Market Challenges
Table 177. Unfractionated Heparin Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
Table 181. Authors List of This Report
List of Figures
Figure 1. Product Picture of Unfractionated Heparin
Figure 2. Global Unfractionated Heparin Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Unfractionated Heparin Market Share by Type: 2024 & 2031
Figure 4. Heparin Sodium Product Picture
Figure 5. Heparin Calcium Product Picture
Figure 6. Global Unfractionated Heparin Market Value by Application (2020-2031) & (US$ Million)
Figure 7. Global Unfractionated Heparin Market Share by Application: 2024 & 2031
Figure 8. Deep Vein Thrombosis (DVT)
Figure 9. Pulmonary Embolism (PE)
Figure 10. Myocardial Infarction
Figure 11. Unstable Angina
Figure 12. Atrial Fibrillation-related Clots
Figure 13. Other
Figure 14. Global Unfractionated Heparin Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Unfractionated Heparin Market Size (2020-2031) & (US$ Million)
Figure 16. Global Unfractionated Heparin Sales (2020-2031) & (K Dose)
Figure 17. Global Unfractionated Heparin Average Price (US$/Dose) & (2020-2031)
Figure 18. Unfractionated Heparin Report Years Considered
Figure 19. Unfractionated Heparin Sales Share by Manufacturers in 2024
Figure 20. Global Unfractionated Heparin Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Unfractionated Heparin Players: Market Share by Revenue in Unfractionated Heparin in 2024
Figure 22. Unfractionated Heparin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Unfractionated Heparin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 25. North America Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 26. U.S. Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 29. Europe Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 30. Germany Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Unfractionated Heparin Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Unfractionated Heparin Revenue Market Share by Region (2020-2031)
Figure 37. China Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Taiwan Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Indonesia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Thailand Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Malaysia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Philippines Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Latin America Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 48. Latin America Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 49. Mexico Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Brazil Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Argentina Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Unfractionated Heparin Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Unfractionated Heparin Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE Unfractionated Heparin Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Unfractionated Heparin by Type (2020-2031)
Figure 58. Global Revenue Market Share of Unfractionated Heparin by Type (2020-2031)
Figure 59. Global Unfractionated Heparin Price (US$/Dose) by Type (2020-2031)
Figure 60. Global Sales Market Share of Unfractionated Heparin by Application (2020-2031)
Figure 61. Global Revenue Market Share of Unfractionated Heparin by Application (2020-2031)
Figure 62. Global Unfractionated Heparin Price (US$/Dose) by Application (2020-2031)
Figure 63. Unfractionated Heparin Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232